G01N 2800/06
Gastro-intestinal diseases
G01N2800/06 (Gastro-intestinal diseases) appears on 583 US grants and 1,174 published applications in this corpus.
Search patents in G01N- Granted patents
- 583
- Published applications
- 1,174
- Assignees
- 516
- Inventors
- 1,975
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 7 | 0 |
| 2000 | 4 | 0 |
| 2001 | 3 | 6 |
| 2002 | 6 | 9 |
| 2003 | 7 | 14 |
| 2004 | 5 | 24 |
| 2005 | 4 | 14 |
| 2006 | 13 | 42 |
| 2007 | 9 | 38 |
| 2008 | 11 | 35 |
| 2009 | 22 | 45 |
| 2010 | 17 | 48 |
| 2011 | 29 | 39 |
| 2012 | 16 | 54 |
| 2013 | 27 | 53 |
| 2014 | 18 | 43 |
| 2015 | 22 | 57 |
| 2016 | 25 | 56 |
| 2017 | 32 | 73 |
| 2018 | 40 | 79 |
| 2019 | 41 | 69 |
| 2020 | 48 | 71 |
| 2021 | 40 | 58 |
| 2022 | 36 | 71 |
| 2023 | 22 | 48 |
| 2024 | 28 | 57 |
| 2025 | 27 | 35 |
| 2026 | 18 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Metabolic biomarkers of inflammatory bowel disease6 Oct 2026US 12,754,192 B2Institut de Cardiologie de Montreal
- Method for diagnosing autoimmune gastritis15 Sep 2026US 12,736,532 B2EUROIMMUN Medizinische Labordiagnostika AG
- Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases7 Jul 2026US 12,673,974 B2Protagonist Therapeutics, Inc.
- Diagnostic marker for pancreatic cancer30 Jun 2026US 12,668,831 B2Urteste S.A.
- Metabolites as diagnostics for autism spectrum disorder in children with gastrointestinal symptoms30 Jun 2026US 12,669,511 B2Arizona Board of Regents on behalf of Arizona State University
- C3-HNE Assay8 Oct 2026US 2026/0309721 A1Nordic Bioscience A/S
- A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer1 Oct 2026US 2026/0297088 A1Antares Therapeutics, Inc.
- Predicting non-responsiveness of ibd patients1 Oct 2026US 2026/0298945 A1Navolab Diagnosztika Kft.
- Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases24 Sep 2026US 2026/0285908 A1Protagonist Therapeutics, Inc.
- Method for determining intestinal permeability17 Sep 2026US 2026/0276634 A1Biomedal, S.L.
Most cited
By later US patents
- Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth243US 6,861,053 B1Cedars-Sinai Medical Center · 2005
- Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions198US 7,048,906 B2Cedars-Sinai Medical Center · 2006
- Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens96US 6,033,864 AThe Regents of the University of California · 2000
- Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia84US 7,081,239 B2Cedars-Sinai Medical Center Burns and Allen Research Center · 2006
- Methods of treating diarrhea caused by small intestinal bacterial overgrowth81US 7,935,799 B2Cedars-Sinai Medical Center · 2011